EGFR and glioma: In the present review, the authors have summarized epidemiology and risk factors associated with GBM, RTKs, and their inhibitors of intracellular signaling pathways in glioma, the clinical profile of small molecule inhibitors (EGFR–TKIs) drugs, and the associated multiple failures/resistance.